Moderna Inc is poised to make regulatory filings in the US and Europe today for its Covid-19 vaccines. This follows the release of new data from a Phase 3 study showing that the messenger RNA (mRNA) vaccine achieved an efficacy rate of 94.1%. The placebo-controlled study involves 30,000 participants.
A new drug combination has received an emergency use authorisation (EUA) from the US Food and Drug Administration for adults and children in hospital with Covid-19 and requiring supplemental oxygen or other life support measures. The treatment combines the anti-viral drug remdesivir with baricitinib, a marketed medicine for rheumatoid arthritis.
Bamlanivimab, a monoclonal antibody directed against the coronavirus spike protein, has been cleared by the US Food and Drug Administration for use in patients with mild-to- moderate Covid-19. The emergency use authorisation (EUA) was issued on 9 November.
A new medical device designed to reduce sleep disturbances in adults affected by post-traumatic stress disorder has been approved by the US Food and Drug Administration. The digital device is intended for use with prescribed medications for the disorder and other recommended therapies for stress-related nightmares.
From the personal computer to the iPhone, digital technologies have long been a feature of global communications. More recently, they have also begun to alter the landscape in healthcare. This was one of the themes addressed by Zaïde Frias of the European Medicines Agency to attendees of the Medtech & Pharma Platform virtual conference on 22 October. Ms Frias is head of the digital business transformation task force at the EMA, one of four groups set up by the agency in early March to prepare for new medical technologies.
The anti-viral treatment Veklury (remdesivir) has been authorised in the US for the treatment of patients with Covid-19 who require hospitalisation – the first coronavirus treatment to receive a full Food and Drug Administration approval. Announced on 22 October, the decision covers the drug’s use for patients 12 years and older. It follows the agency’s more restrictive emergency use authorisation (EUA) for Veklury, issued in May, which will now only cover the drug’s use in young children.
The European Medicines agency is recommending conditional approval of Tecartus (autologous anti-CD19-transduced CD3+ cells) for the treatment of relapsed or refractory mantle cell lymphoma. The chimeric antigen receptor (CAR) T cell therapy is the third medicine of its type to be reviewed by the agency. It follows the 2018 approvals of Kymriah for leukaemia and lymphoma and Yescarta for lymphoma.
The US Food and Drug Administration has given its first approval to a treatment for Ebola virus, a potentially fatal disease affecting people in the Democratic Republic of the Congo (DRC) and several other African countries. The treatment, Inmazeb, is a mixture of three monoclonal antibodies which bind to the glycoprotein on the surface of the virus, blocking its attachment to cell receptors and preventing its entry into cells.
Switzerland-based Santhera Pharmaceuticals AG has discontinued development of Puldysa (idebenone), its candidate therapy for Duchenne muscular dystrophy after an independent review of an ongoing Phase 3 trial concluded that the trial was unlikely to meet its primary endpoint. The Data and Safety Monitoring Board based its conclusion on an interim analysis of the study, SIDEROS, which was being conducted in Duchenne muscular dystrophy patients using concomitant glucocorticoids.
The European Medicines Agency has started a rolling review of a prospective vaccine for Covid-19 being developed by Oxford University and AstraZeneca Plc on the basis of preliminary data showing that it triggered the production of antibodies and T cells that target the virus. The agency announced the review on 1 October.